Home > Journals > Giornale Italiano di Dermatologia e Venereologia > Past Issues > Articles online first > Giornale Italiano di Dermatologia e Venereologia 2017 Jan 12

CURRENT ISSUE
 

ARTICLE TOOLS

Reprints
Cite this article as

GIORNALE ITALIANO DI DERMATOLOGIA E VENEREOLOGIA

A Journal on Dermatology and Sexually Transmitted Diseases


Official Journal of the Italian Society of Dermatology and Sexually Transmitted Diseases
Indexed/Abstracted in: EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 1,311


eTOC

 

Giornale Italiano di Dermatologia e Venereologia 2017 Jan 12

DOI: 10.23736/S0392-0488.17.05524-9

Copyright © 2017 EDIZIONI MINERVA MEDICA

language: English

Serum tryptase levels in melanoma patients: case-control study and review of the literature

Giovanni PAOLINO 1, Elisa MOLITERNI 1, Dario DIDONA 2*, Michele CARDONE 1, Teresa LOPEZ 1, Valentina GARELLI 1, Antonio G. RICHETTA 1, Ugo BOTTONI 3, Carmen CANTISANI 1, Alfredo ROSSI 1, Stefano CALVIERI 1

1 Clinica Dermatologica, La Sapienza-Università di Roma, Rome, Italy; 2 Istituto Dermopatico dell’Immacolata-IRCCS, Rome, Italy; 3 Università della Magna Graecia, Catanzaro, Italy


PDF  


BACKGROUND: Serum tryptase results from the constant release of the enzyme from mast cells and serum tryptase levels are commonly considered to be related to the total number of mast cells. They are increased in several malignancies, as pancreatic carcinoma, angiosarcoma, hepatic carcinoma and proliferative and/or non- proliferative hematological disorders. Contrariwise, it has been reported that the number of tryptase+ and chymase+ mast cells was lower in deeply invasive melanoma compared to in-situ melanoma and dysplastic nevi. Considering the underlying pathophysiological linkages between mast cells and melanocytes and that serum tryptase is related to angiogenesis, tissue-degrading proprieties and metastatization, we have decided to evaluate serum tryptase levels in melanoma patients and in a healthy control.
METHODS: We performed a case-control study evaluating serum tryptase in melanoma and in healthy group. Starting from an initial general analysis, we have performed a sub-analysis for each sample.
RESULTS: In general population serum tryptase was statistically higher in elderly patients. Generally, in melanoma patients, median serum tryptase was in lower normal range. We found a decreasing of serum tryptase levels from the healthy control to thin (≤ 1.00 mm Breslow thickness), reaching the lowest levels in thicker melanoma (≥ 1.01 m Breslow thickness), in ulcerated and metastatic melanoma.
CONCLUSION: Tryptase may have a protective role in melanoma or, conversely, it may play a role in the early stage of the tumorigenesis. Serum tryptase is an easy and useful biomarker to better investigate melanoma biology.


KEY WORDS: Serum tryptase - Mast cells – Melanoma – Prognosis - Metastasis

top of page

Publication History

Cite this article as

Paolino G, Moliterni E, Didona D, Cardone M, Lopez T, Garelli V, et al. Serum tryptase levels in melanoma patients: case-control study and review of the literature. G Ital Dermatol Venereol 2017 Jan 12. DOI: 10.23736/S0392-0488.17.05524-9 

Corresponding author e-mail